Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression by Junye Liu et al.
Liu et al. BMC Cancer 2012, 12:370
http://www.biomedcentral.com/1471-2407/12/370RESEARCH ARTICLE Open AccessKnock-down of NDRG2 sensitizes cervical cancer
Hela cells to cisplatin through suppressing Bcl-2
expression
Junye Liu1,2†, Le Yang2,3†, Jian Zhang2, Jing Zhang2, Yongbin Chen1, Kangchu Li1, Yurong Li1, Yan Li2,
Libo Yao2* and Guozhen Guo1*Abstract
Background: NDRG2, a member of N-Myc downstream regulated gene family, plays some roles in cellular stress,
cell differentiation and tumor suppression. We have found that NDRG2 expression in cervical cancer Hela cells
increases significantly upon stimulation with cisplatin, the most popular chemotherapeutic agent currently used for
the treatment of advanced cervical cancer. This interesting phenomenon drove us to evaluate the role of NDRG2 in
chemosensitivity of Hela cells.
Methods: In the present study, RNA interference was employed to down-regulate NDRG2 expression in Hela cells.
RT-PCR and Western blot were used to detect expression of NDRG2, Bcl-2 and Bax in cancer cells. Real-time PCR
was applied to detect miR-15b and miR-16 expression levels. Drug sensitivity was determined with MTT assay. Cell
cloning efficiency was evaluated by Colony-forming assay. Apoptotic cells were detected with annexin V staining
and flow cytometry.
Results: In vitro drug sensitivity assay revealed that suppression of NDRG2 could sensitize Hela cells to cisplatin.
Down-regulation of NDRG2 didn’t influence the colony-forming ability but promoted cisplatin-induced apoptosis of
Hela cells. Inhibition of NDRG2 in Hela cells was accompanied by decreased Bcl-2 protein level. However, Bcl-2
mRNA level was not changed in Hela cells with down-regulation of NDRG2. Further study indicated that miR-15b
and miR-16, two microRNAs targetting Bcl-2, were significantly up-regulated in NDRG2-suppressed Hela cells.
Conclusions: These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to
cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16.
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Cervical cancer is the second largest cause of cancer mor-
tality in women worldwide with more than 270,000 deaths
per year [1]. Current therapies for the treatment of
advanced cervical cancer involve the use of cisplatin, often
in combination with radiotherapy [2]. Cisplatin is believed
to act via the formation of inter- and intrastrand cross-
links in DNA, culminating in the initiation of cell death* Correspondence: bioyao@fmmu.edu.cn; guozhen@fmmu.edu.cn
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reproduction in any medium, provided the orvia caspases [3]. Unfortunately, the current cisplatin-based
treatment for cervical cancer does not lead to a high
disease-free survival rate in patients with bulky or locally-
advanced disease. To develop new potentially therapeutic
treatments for cancers, two strategies have been devel-
oped. The first strategy uses an approach to identify po-
tential mechanisms of resistance to cancer therapy, and to
overcome these resistance phenotypes using specific re-
sistance modulators [4]. The second strategy seeks to cor-
relate biological features with genetic alterations in cancer
cell [5]. Although some progress has been achieved in the
past three decades, much more efforts are still needed to
resolve cisplatin-resistance of cervical cancer.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gene (NDRG) family, was first cloned in our laboratory
in 1999 (GenBank accession no. AF159092). NDRG
gene family represents a new class of Myc-repressed
genes which also consist of NDRG1, NDRG3 and
NDRG4 [6]. The NDRGs share 57-65% amino acid
identity and are highly conserved in plants, inverte-
brates and mammals, suggesting that this gene family
may have important cellular functions. Although
NDRG2 has been implicated in cellular stress [6], it’s
physiological function still remains unclear. Interest-
ingly, NDRG2 has been found to be deregulated in
many kinds of human malignant tumors [7-17]. We
previously reported that NDRG2 could be up-regulated
by hypoxia and radiation and could promote radiore-
sistance of human cervical cancer Hela cells [18]. In
another study, we found adriamycin enhanced NDRG2
expression in several tumor cell lines [19]. This led us
to further explore whether NDRG2 has a role in regu-
lation of cisplatin-sensitivity of cervical cancer cells.Methods
Cell culture
The human cervical cancer cell line Hela was obtained
from the American Type Culture Collection (Manassas,
VA) and maintained as a monolayer in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Sijiqing Biological
Engineering Materials Co., Hangzhou, China) at 37°C in
the presence of 5% CO2-balanced air.Constructs and transfection
The recombinant pSilencer 3.1 (Ambion, Austin, TX)
constructs expressing a scramble control small interfer-
ence RNA (siRNA) or siRNA specific to NDRG2 have
been described previously [20]. All construct sequences
were directly confirmed by DNA sequencing. Hela cells
were transfected with the corresponding constructs
using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instruction.
RT-PCR
Total RNA was extracted from Hela cells using Trizol re-
agent according to instructions provided by the manufac-
turer (Invitrogen, Carlsbad, CA). cDNAs were obtained by
reverse transcription using Revert Aid First Strand cDNA
Synthesis Kit (Fermentas, Shenzhen, Guangzhou, China)
with 2 μg of total RNA. The RT-PCR exponential phase
was determined on 25–30 cycles to allow semi-
quantitative comparisons among cDNAs developed from
identical reactions. Each PCR involved a 94°C, 5 min ini-
tial denaturation step followed by 35 cycles (for NDRG2)
at 94°C for 30 s, 52°C for 40 s, and 72°C for 40 s, 20 cycles(for β-actin) at 94°C for 30 s, 55°C for 10 s, and 72°C for
30 s, 25 cycles (for Bcl-2) at 94°C for 30 s, 62°C for 30 s,
and 72°C for 30 s, then 72°C, 10 min extension step.
Oligonucleotide primer sequences for NDRG2 [20], Bcl-2
[21] and β-actin [21] have been described previously. The
PCR products were separated by electrophoresis on 1.5%
agarose gels.Real-time PCR
NDRG2 and Bcl-2 mRNA expression levels were evalu-
ated by real-time PCR using the ABI PRISM 5700 se-
quence detection system (Applied Biosystems, Foster
City, CA). Primers for NDRG2 have been described pre-
viously [12]. The primer sequences for Bcl-2 were: 5'-
GGTGAACTGGGGGAGGATTGT-3' for the forward
primer, and 5'-CTTCAGAGACAGCCAGGAGAA-3' for
the reverse primer. Fluorescent data were converted into
cycle threshold measurements using the SDS system
software and exported to Microsoft Excel. Fold expres-
sion changes relative to Hela cells were calculated with
the ΔΔCT method [22] using ARF1 (ADP-ribosylation
factor 1) as the reference transcript [12].
For detection of microRNAs (miRNA), stem-loop re-
verse transcription followed by real-time PCR analysis
was performed as previously described [21]. The primers
used for stem-loop RT-PCR for Let-7a [23], miR-15b
[21] and miR-16 [21] have been reported elsewhere. The
relative amount of each miRNA was normalized to U6
snRNA. The fold-change for each miRNA relative to the
Hela cells was calculated using ΔΔCT method [22]. PCR
was performed in triplicate.Western blot analysis
Hela cells and their variants were solubilized in lysis buffer
containing 20 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton
X-100, 5 mM EDTA, 10 μg/ml leupeptin, 10 μg/ml aproti-
nin, 1 mM phenylmethylsulfonyl fluoride. Fifty micro-
grams of cell lysate was resolved by SDS-PAGE and
transferred to nitrocellulose membranes (0.22 μm, Milli-
pore, Bedford, MA). The blots were probed with anti-
bodies (from Santa Cruz Biotechnology, Santa Cruz, CA,
unless otherwise indicated) against NDRG2, NDRG1, Bcl-
2, Bax, P-glycoprotein, multidrug resistance protein,
caspase-3 (Cell Signaling Technology, Danvers, MA) or
caspase-9 (Cell Signaling Technology), followed by incu-
bation in a species-matched horseradish peroxidase
(HRP)-conjugated secondary antibody. The blots were
developed with a chemiluminescence substrate solution
(Pierce, Rockford, IL) and exposed to X-ray film. Equal
loading of all lanes was confirmed by reprobing the mem-
branes with anti-β-actin antibody (Sigma, St. Louis, MO).
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The effect of cisplatin on growth of Hela and its variants
was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay as previously
described [24]. Briefly, 2000 cells were plated into 96-
well plates in 200 μl aliquots and allowed to adhere
overnight before cisplatin (Qilu Pharmaceutical Co Ltd,
Jinan, Shandong, China) was added. The final concentra-
tions of cisplatin were as 0.01, 0.1, 1, 10 and 100 times
of human peak plasma concentration of cisplatin (2 μg/
ml) [24], respectively. After incubation with cisplatin at
37°C for 72 h, 20 μl aliquots of an MTT solution (5 mg/
ml) were added to each well and plates were incubated
for an additional 4 h at 37°C. The media was then
removed and replaced with 150 μl of 100% DMSO to
dissolve the formazan crystals with agitation for 5–
10 min on a shaker. The absorbance was measured at
490 nm using a multiwell scanning spectrophotometer
(Molecular Devices, Sunnyvale, CA). Cell viability was
expressed as A490 percentage of untreated cells. The
IC50 values were determined from a plot of cell viability
using probit module of SPSS software (version 10.0;
SPSS, Chicago, IL). Three replicates were performed for
each experimental condition.
Colony-forming assay
Cells were seeded on six-well tissue culture plates with 500
cells per well and incubated in complete medium with or
without cisplatin (2, 5, 10 μg/ml). After 12 days of culture,
colonies of surviving cells were counted and the cloning ef-
ficiency was calculated in comparison to seeded cells.
Detection of apoptosis
Hela cells and their variants were treated with cisplatin at
desired concentration for 24 h. The apoptotic cells were
stained with fluorescein isothio-cyanate (FITC)-labeled
annexin V (Roche Applied Science, Basel, Switzerland)
and propidium iodide (PI) as previously described [18].
Apoptotic cells were measured using a Becton Dickinson
fluorescence-activated cell sorter (FACS) apparatus.
Statistical analysis
Data are expressed as mean ± SD. Statistical analyses
were performed with the SPSS software (version 10.0;
SPSS, Chicago, IL) by using one-way ANOVA followed
by the t-test for independent groups. A p level of < 0.05
was considered statistically significant.Figure 1 NDRG2 expression in Hela cells was enhanced by
cisplatin. Hela cells were exposed to cisplatin (5 μg/ml) for the
indicated time. NDRG2 expression was evaluated by RT-PCR (A) and
Western blot (B) analysis. β-actin served as internal control. Shown
are representative of 3 independent experiments.Results
NDRG2 expression was enhanced in Hela cells exposed to
cisplatin
In the present study, the effect of cisplatin on NDRG2 ex-
pression was evaluated in human cervical cancer Helacells. Hela cells were exposed to cisplatin at concentration
of 2, 5, 7,10 μg/ml, respectively. It was found cisplatin up-
regulated NDRG2 expression in Hela cells, with the most
prominent effects of cisplatin on NDRG2 expression were
seen at concentration of 5 μg/ml (data not shown). As
indicated in Figure 1, NDRG2 mRNA (Figure 1A) and
protein (Figure 1B) levels significantly increased upon in-
cubation with 5 μg/ml of cisplatin. The change of NDRG2
was time-dependent and sustained at least for 24 h. These
suggested that NDRG2 might be involved in drug re-
sponse and chemosensitivity of Hela cells.Down-regulation of NDRG2 sensitized Hela cells to
cisplatin
To address the role of NDRG2 in chemosensitivity of Hela
cells, Hela cells were transfected with DNA constructs
expressing NDRG2-specific siRNA or scramble control.
The G418-resistant mix clones were selected for further
experiments. As shown in Figure 2D, NDRG2-specific
siRNA resulted in significantly inhibited NDRG2 expres-
sion with no obvious change of NDRG1 in Hela cells.
Colony-forming assay was employed to determine the ef-
fect of NDRG2 on cell growth. It was found that inhibition
of NDRG2 didn’t alter the colony-forming ability in the
absence of cisplatin but did enhance the suppressive effect
of cisplatin on colony-forming ability of Hela cells
(Figure 2A). The cell viability in the presence of cisplatin
was further evaluated with MTT assay. It was indicated
down-regulation of NDRG2 resulted in poor cell viability
(Figure 2B). The IC50 values of Hela cells to cisplatin were
calculated from the cell viability plots. As displayed by
Figure 2C, suppression of NDRG2 was accompanied by
significantly decreased IC50 values. These data indicated
that down-regulation of NDRG2 could increase sensitivity
of Hela cells to cisplatin.
Figure 2 Down-regulation of NDRG2 sensitized Hela cells to cisplatin. Hela cells were transfected with pSilencer3.1 constructs expressing
NDRG2-specific siRNA (siNDRG2) or scramble control. The G418-resistant mix clones were selected for further assays. A. The colony-formation
ability of Hela cells and their variants was evaluated in the presence or absence of cisplatin (CDDP). B. Cell viability was evaluated by MTT assay as
described in “Materials and Methods” and plotted against CDDP concentration. C. The IC50 values were determined according to the plot.
* p < 0.01 vs Hela and scramble control. D. Down-regulation of NDRG2 in stable clones was displayed by Western blot with β-actin as loading
control. Shown are representative of 3 independent experiments. * p < 0.01 vs Hela and scramble control. # p < 0.05 vs Hela and scramble control.
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apoptosis
The mechanisms underlying NDRG2 effect on chemosen-
sitivity were further explored. Considering NDRG2 has no
influence on colony-forming ability and most kinds of
chemotherapeutic drugs inhibit tumor growth through in-
ducing apoptosis of cancer cells, the effect of NDRG2 on
cisplatin-induced apoptosis was evaluated. Hela cells and
their stable variants were treated with cisplatin at different
concentration and apoptotic cells were examined with
flow cytometry. In the absence of cisplatin, Hela cells and
their variants displayed similar spontaneous apoptotic rate
(Figure 3A). Treatment of cisplatin increased apoptosis of
each kind of cells at dose-dependent manner. Hela cells
with down-regulated NDRG2 had highest apoptotic rate
among those 3 kinds of cells (Figure 3A), indicating inhib-
ition of NDRG2 significantly enhanced cisplatin-induced
apoptosis of Hela cells.
To validate the effect of NDRG2 on apoptosis, we fur-
ther analyzed the proteolytic maturation of caspase-9 and
caspase-3 triggered by CDDP. As indicated in Figure 3B,
whereas CDDP induced a minor yet detectable increase in
the abundance of the cleaved fragments of both caspase-9
and caspase-3 in Hela and scramble control cells,
siNDRG2 cells responded to CDDP by massively activat-
ing caspases as well as significantly decreased procaspase-9 and procaspase-3. Comparing to scramble control,
siNDRG2 cells exhibited similar levels of procaspase-9
and procaspase-3 (Figure 3B), suggesting no obvious influ-
ence of NDRG2 on caspase expression.
Suppression of NDRG2 inhibited Bcl-2 expression in Hela
cells
To further illustrate the role of NDRG2 in cisplatin-
induced apoptosis, the expression of Bax and Bcl-2
was examined in Hela cells and their variants by
Western blot. Comparing to Hela cells, the scramble
control cells showed slightly but not significantly
increased levels of NDRG2 and Bcl-2 (Figure 4).
siNDRG2 cells exhibited down-regulation of NDRG2
as well as significantly repression of Bcl-2 in compari-
son with Hela and scramble control (Figure 4). Al-
though both scramble control and siNDRG2 cells
showed much lower level of Bax than Hela cells, there
was no significant difference of Bax between scramble
control and siNDRG2 cells (Figure 4), indicating no
obvious relation of Bax to knock-down of NDRG2. In
addition, P-glycoprotein and multidrug resistance pro-
tein, two transporters associated with cancer drug re-
sistance including cisplatin resistance [25], were not
influenced by NDRG2 in Hela cells (Figure 4). These
data suggested that down-regulation of NDRG2
Figure 3 Down-regulation of NDRG2 enhanced cisplatin-induced apoptosis of Hela cells. Hela cells and the stable variants were exposed
to different concentration of cisplatin (CDDP) for 24 h. The apoptotic cells were either stained with annexin V-FITC and propidium iodide (PI) and
examined with flow cytometry, or subjected to Western blot. A. The percentage of apoptotic cells was presented. # p < 0.05 vs Hela and scramble
control. * p < 0.01 vs Hela and scramble control. B. The expression of caspase-3 (Casp-3) and caspase-9 (Casp-9) was detected by Western blot
analysis using β-actin as loading control. Shown are representative of 3 independent experiments. Act, active caspase. Pro, procaspase.
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Bcl-2/Bax ratio, which might in turn increase the sen-
sitivity of Hela cells to cisplatin-induced apoptosis.
NDRG2 modulated Bcl-2 expression through regulating
miR-15b and miR-16
The mRNA level of Bcl-2 in Hela cells and their variants
was determined to address if NDRG2 transcriptionally
regulated Bcl-2 expression. As revealed by RT-PCR, Hela
cells expressing NDRG2-specific siRNA exhibited
reduced NDRG2 mRNA level in comparison with
scramble control cells (Figure 5A). However, Bcl-2
mRNA level was not changed by down-regulation of
NDRG2 (Figure 5A). Real-time PCR was further
employed to detect Bcl-2 and NDRG2 expression in
Hela cells and their variants. It was shown Hela cells
and their variants harbored similar level of Bcl-2 mRNA
(Figure 5B), indicating NDRG2 regulated Bcl-2Figure 4 Suppression of NDRG2 inhibited Bcl-2 expression in Hela ce
resistance protein (MRP) in Hela and its stable variants was evaluated by W
of 3 independent experiments. B. Densitometric analysis of Western blot as
Hela cells as reference. * p < 0.01 vs Hela and scramble control. Δ p< 0.01 vexpression at post-transcriptional level. miR-15b and
miR-16, two microRNAs that had been reported to tar-
get Bcl-2 and inhibit Bcl-2 protein expression [21], were
evaluated in Hela cells and their variants. It was found
miR-15b and miR-16 significantly increased in Hela cells
expressing NDRG2-specific siRNA comparing to Hela
parental cells and scramble control (Figure 5B). Another
microRNA, Let-7a, was not changed in those 3 kinds of
cells. These data suggested that down-regulation of
NDRG2 resulted in increased expression of miR-15b and
miR-16, which subsequently inhibited translation of Bcl-
2 and led to reduced expression of Bcl-2 protein.
Discussion
Platinum-based drugs, and in particular cisplatin, are
widely used for the treatment of many kinds of solid ma-
lignancies, including cervical cancer [2]. Cisplatin often
leads to an initial therapeutic success associated withlls. A. The expression of Bcl-2, Bax, P-glycoprotein (P-gp) and multidrug
estern blot with β-actin as loading control. Shown are representative
say was further performed. Data was expressed as fold change using
s Hela. # p > 0.05 vs scramble control.
Figure 5 Suppression of NDRG2 did not change Bcl-2 mRNA level but increased expression of miR-15b and miR-16 in Hela cells. The
mRNA expression of NDRG2 and Bcl-2 was evaluated by RT-PCR (A) with β-actin as loading control. The expression of NDRG2, Bcl-2 and
microRNAs (let-7a, miR-15b, miR-16) in Hela and its stable variants was determined by real-time PCR (B) as described in “Materials and Methods”.
Fold expression changes relative to Hela cells were calculated. * p < 0.01 vs Hela and scramble control.
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patients developed resistance to cisplatin before and
even after exposing to this chemotherapeutic agent. It is
widely accepted that the high incidence of chemoresis-
tance is the main reason for cisplatin treatment failure.
Although the pre-target, on-target, post-target and off-
target mechanisms of cisplatin-resistance have been pro-
posed recently [25], the molecular mechanisms under-
lying cisplatin-resistance are still far from understood.
In the present study, we provide evidence that NDRG2
is involved in the regulation of cisplatin-resistance of
cervical cancer cells. Firstly, it was shown that cisplatin
treatment induced up-regulation of NDRG2 in a time-
dependent manner. Secondly, knock-down of NDRG2
by siRNA increased the suppressive effects of cisplatin
on colony-forming ability of Hela cells. Thirdly, inhib-
ition of NDRG2 significantly lowered the IC50 values of
cisplatin for Hela cells, indicating down-regulation of
NDRG2 increased the sensitivity of Hela cells to cis-
platin. Finally, down-regulation of NDRG2 resulted in
decreased expression level of Bcl-2, one of important
regulators of apoptosis and drug resistance.
NDRG2, similar to NDRG1, has been proposed to be
involved in cell stress [6]. Previous studies demonstrated
that NDGR2 expression in cancer cell lines could be
enhanced by adriamycin [19], hypoxia [20] and radiation
[18], and that NDRG2 was implicated in regulation of
adriamycin-induced apoptosis [19] and radioresistance
[18]. All those data support a role of NDRG2 in cell
stress. It is well-characterized that the mode of action of
cisplatin involves the DNA-damage response and mito-
chondrial apoptosis [26,27]. From this view, it is reason-
able that NDRG2 can be induced by cisplatin. In line
with previous reports, the present study indicates modu-
lation of NDRG2 expression occurs at transcriptional
level. Although NDRG2 transcription can be suppressed
by Myc [28], several binding sites for hypoxia-inducible
factor 1 (HIF-1) have been found in the promoter regionof NDRG2 gene and HIF-1 is responsible for NDRG2
up-regulation induced by hypoxia and radiation [18,20].
It has been reported that HIF-1 can be activated by vin-
cristine in gastric cancer cells under normoxic condition
[29]. Cisplatin, as a chemotherapeutic drug like adriamy-
cin and vincristine, might induce NDRG2 expression
through activation of HIF-1. However, this speculation
needs to be validated in future study.
It is well known that Bcl-2 and Bax play critical roles
in mitochondria apoptosis. As discussed in a recently
published review [25], there are increasing evidences
that overexpression of Bcl-2 confers multidrug resistance
and that clinical data have linked Bcl-2 expression level
with cisplatin resistance and recurrent disease. The
present study revealed that suppression of NDRG2 sig-
nificantly inhibited Bcl-2 expression, which depictes how
does NDRG2 influence cisplatin-induced apoptosis of
Hela cells. Interestingly, NDRG2 regulates Bcl-2 expres-
sion at post-transcriptional level. It has been well defined
that Bcl-2 can be targeted and regulated by microRNAs
such as miR-15b and miR-16 in gastric cancer cells [21].
These microRNAs bind to the 3’ untranslational region
of Bcl-2 mRNA and inhibit translation of Bcl-2 protein
without changing mRNA level. Similarly, the present
study indicated that down-regulation of NDRG2 resulted
in increased level of miR-15b and miR-16, which might
in turn reduce Bcl-2 protein expression. However, the
study does not exclude the possibility that NDRG2 influ-
ences stabilization of Bcl-2 protein.
It has been well documented that hypoxia- and
radiation-induced NDRG2 promotes resistance of Hela
cells to radiation [18]. The present study demonstrated
that cisplatin-induced NDRG2 increases chemoresis-
tance of Hela cells. Considering cisplatin is often used in
combination with radiotherapy for advanced cervical
cancer [2], NDRG2 may represent a key regulator of
therapy-resistance in cervical cancer cells. It should be
noted that NDRG2 has been proposed as a potential
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showed that the level of NDRG2 was reduced in many
kinds of malignant tumor comparing to the normal
counterpart and that NDRG2 level was an independent
prognostic factor for cancer patients [7-17]. It was also
reported that restoration of NDRG2 could inhibit prolif-
eration of cancer cells [6]. Recently, the crystal structure
of human NDRG2 protein was resolved and NDRG2
was proposed to suppress TCF/β-catenin signaling in the
tumorigenesis of human colorectal cancer via a molecu-
lar interaction [30]. Moreover, a role for NDRG2 in the
oncogenic properties of renal cell carcinoma has been
suggested [31]. However, these data cannot exclude the
possibility of NDRG2 to promote drug and radiation re-
sistance. We proposed NDRG2 as a multifunctional pro-
tein. As a tumor suppressor, NDRG2 is inhibited to
facilitate tumor development in the process of tumori-
genesis. As a resistance regulator, NDRG2 may be re-
activated or up-regulated to promote cancer cell survival
during or after chemotherapy/radiotherapy. In an early
study, it was shown inhibition of NDRG2 resulted in
slightly increased proliferation and cisplatin resistance as
well as decreased Fas expression and Fas-mediated cell
death in gastric cancer cells [9]. The discrepancy of
NDRG2 in cisplatin resistance in cervical cancer and
gastric cancer cells may due to tissue specificity. How-
ever, our speculation needs supporting data from further
studies. It will be helpful to validate the role of NDRG2
in cisplatin resistance in multiple cell lines other than
Hela and to explore the clinical relevance of NDRG2 to
cisplatin resistance in patients with cervical cancer.Conclusions
The present study demonstrated that NDRG2 can be
induced in Hela cells by cisplatin in a time-dependent man-
ner and that knock-down of NDRG2 by siRNA increases
sensitivity of Hela cells to cisplatin. Down-regulation of
NDRG2 could enhance cisplatin-induced apoptosis of Hela
cells through inhibiting Bcl-2 protein expression, which
might be mediated by up-regulating miR-15b and miR-16.
These data can help us to better understand the molecular
mechanisms of cisplatin-resistance and the precise role of
NDRG2 in tumor development.
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